Overview and Scope
Lysosomal diseases (LSDs) refer to diseases in which substrates accumulate in excess in the cells of various organs due to defective lysosomal function. The accumulation of materials in the lysosomes leads to damage in various tissues and organs, resulting in a wide range of symptoms that can affect different parts of the body.
Sizing and Forecast
The lysosomal disease treatment market size has grown strongly in recent years. It will grow from $8.69 billion in 2023 to $9.33 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to advancements in therapeutic approaches, improved understanding and awareness, rise in clinical trials and research efforts, enhancements in diagnostic tools, development of newborn screening programs..
The lysosomal disease treatment market size is expected to see strong growth in the next few years. It will grow to $12.58 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to gene therapy advancements, continued developments in enzyme replacement therapy (ert), expansion of new therapeutic modalities, enhanced screening and early diagnosis programs, investments in research and development.. Major trends in the forecast period include advancements in enzyme replacement therapy (ert), gene therapy innovations, chaperone therapy development, substrate reduction therapy (srt), expansion of newborn screening programs..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/lysosomal-disease-treatment-global-market-report
Segmentation & Regional Insights
The lysosomal disease treatment market covered in this report is segmented –
1) By Disease Type: Mucopolysaccharidosis, Pompes Syndrome, Fabry Diseases, Gaucher’s Disease, Other Disease Types
2) By Therapy: Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy, Other Therapies
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End User: Hospitals, Specialty Clinics, Homecare, Other End Users
North America was the largest region in the lysosomal disease treatment market in 2023. Europe is expected to be the fastest-growing region in the global lysosomal disease treatment market report during the forecast period. The regions covered in the lysosomal disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10482&type=smp
Major Driver Impacting Market Growth
The rising incidence of lysosomal disorders is expected to propel the growth of the lysosomal disease treatment market going forward. Lysosomal diseases are rare genetic disorders that result in a deficiency of enzymes and the abnormal accumulation of materials in the body. Treatment for these diseases involves degrading stored materials in the lysosome using exogenous enzymes that are synthesized outside the body and infused into the bloodstream. For instance, in December 2021, according to The Lancet, a UK-based peer-reviewed general medical journal, in Australia, the combined prevalence of LSD was 1 per 4,800 live births. There were also 766 confirmed diagnoses of lysosomal storage disorders, which included 38 different disorders, with 32 cases diagnosed prenatally. The average annual incidence per 100,000 live births was 21 (range 16–26), with Fabry disease being the most commonly diagnosed, accounting for 34% of all cases. Additionally, more adults were diagnosed than children, implying that LSD is more common in adulthood than in childhood. Therefore, the rise in the incidence of lysosomal disorders is driving the growth of the home healthcare equipment market.
Key Industry Players
Major companies operating in the lysosomal disease treatment market report are Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Sanofi SA, Pfizer Inc., Novartis International AG, Johnson & Johnson Services Inc., Alexion Pharmaceuticals Inc., Amicus Therapeutics Inc., Actelion Pharmaceuticals Ltd., Sigilon Therapeutics Inc., BioMarin Pharmaceutical Inc., Merck & Co Inc., AstraZeneca PLC, Arena Pharmaceuticals Inc., Astellas Pharma Inc., Horizon Therapeutics plc, Leadient Biosciences Inc., Orphazyme A/S, Recordati Industria Chimica e Farmaceutica S.p.A., Valerion Therapeutics Llc, Viatris Inc., Chiese Farmaceutici SpA, Genzyme Corporation, Ultragenyx Pharmaceutical Inc., Sangamo Therapeutics Inc., Avrobio Inc., Axovant Gene Therapies Ltd., Regenxbio Inc., Krystal Biotech Inc., Homology Medicines Inc., Orchard Therapeutics plc, Sarepta Therapeutics Inc., Solid Biosciences Inc.
The lysosomal disease treatment market report table of contents includes:
1. Executive Summary
2. Lysosomal Disease Treatment Market Characteristics
3. Lysosomal Disease Treatment Market Trends And Strategies
4. Lysosomal Disease Treatment Market – Macro Economic Scenario
5. Global Lysosomal Disease Treatment Market Size and Growth
.
.
.
31. Global Lysosomal Disease Treatment Market Competitive Benchmarking
32. Global Lysosomal Disease Treatment Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Lysosomal Disease Treatment Market
34. Lysosomal Disease Treatment Market Future Outlook and Potential Analysis
35. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
